-
公开(公告)号:EP2568985A4
公开(公告)日:2013-10-23
申请号:EP10851334
申请日:2010-11-22
申请人: MAPI PHARMA LTD
发明人: MAROM EHUD , RUBNOV SHAI
IPC分类号: A61K31/513 , C07D401/04
CPC分类号: A61K31/513 , C07D401/04
-
2.
公开(公告)号:EP2509423A4
公开(公告)日:2013-07-31
申请号:EP10835601
申请日:2010-01-28
申请人: MAPI PHARMA LTD
发明人: MIZHIRITSKII MICHAEL , MAROM EHUD , RUBNOV SHAI
IPC分类号: C07D249/08 , C07D291/06
CPC分类号: C07D249/08 , C07D291/06
-
公开(公告)号:EP3143004A4
公开(公告)日:2017-11-08
申请号:EP14892030
申请日:2014-07-20
申请人: MAPI PHARMA LTD
发明人: RUBNOV SHAI , MAROM EHUD
IPC分类号: C07D209/44 , A61K31/4035
CPC分类号: C07D209/48 , A61K9/14 , A61K31/4035
摘要: The present invention provides a new amorphous form of apremilast, pharmaceutical compositions comprising same, methods for preparation and use thereof in treating conditions mediated by inhibition of TNF-α production or inhibition of phosphodiesterase 4 (PDE4), e.g., psoriatic arthritis and other chronic inflammatory diseases.
-
4.INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD 有权
标题翻译: ZWISCHENVERBINDUNGEN UND VERFAHREN ZUR HERSTELLUNG VON FINGOLIMOD公开(公告)号:EP2632889A4
公开(公告)日:2015-01-07
申请号:EP11835740
申请日:2011-10-27
申请人: MAPI PHARMA LTD
发明人: MAROM EHUD , MIZHIRITSKII MICHAEL , RUBNOV SHAI
IPC分类号: C07C201/12 , C07C205/16 , C07C205/40 , C07C205/45 , C07C215/28 , C07C231/02 , C07D319/06 , C07F9/40 , C07F9/54
CPC分类号: C07C213/02 , C07C201/12 , C07C205/02 , C07C205/31 , C07C205/40 , C07C205/45 , C07C231/02 , C07D319/06 , C07F9/4021 , C07F9/4056 , C07F9/5442 , C07F9/5456 , C07C215/28 , C07C205/16
摘要: The present invention relates to processes for the preparation of (2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (Fingolimod) and pharmaceutically acceptable salts thereof, and intermediates formed in such processes.
摘要翻译: 本发明涉及制备(2-氨基-2- [2-(4-辛基苯基)乙基]丙烷-1,3-二醇盐酸盐(芬戈莫德)及其药学上可接受的盐的方法,以及在这些方法中形成的中间体 。
-
公开(公告)号:EP2410855A4
公开(公告)日:2012-10-17
申请号:EP10755533
申请日:2010-03-25
申请人: MAPI PHARMA LTD
发明人: MAROM EHUD , MIZHIRITSKII MICHAEL , RUBNOV SHAI
IPC分类号: A61K31/513 , C07C275/24 , C07C275/50 , C07D239/545 , C07D239/62 , C07D401/04
CPC分类号: A61K31/513 , C07C275/24 , C07C275/50 , C07D239/545 , C07D239/62 , C07D403/04
-
6.INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF 审中-公开
标题翻译: 中间体化合物及其制造方法鲁拉西及其盐公开(公告)号:EP2736905A4
公开(公告)日:2015-07-29
申请号:EP12817841
申请日:2012-06-13
申请人: MAPI PHARMA LTD
IPC分类号: C07D417/12 , C07D209/44 , C07D209/48 , C07D275/06 , C07D417/14
CPC分类号: C07D417/14 , C07C309/04 , C07D209/44 , C07D209/48 , C07D209/72 , C07D275/04 , C07D417/12
-
公开(公告)号:EP2699317A4
公开(公告)日:2014-12-03
申请号:EP12774372
申请日:2012-04-16
申请人: MAPI PHARMA LTD
发明人: MAROM EHUD , RUBNOV SHAI
IPC分类号: A61P25/28
CPC分类号: C08G69/10 , A61K31/785 , A61K38/00 , A61K45/06 , C07K14/001 , A61K2300/00
-
8.INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS 有权
标题翻译: 中间体及其制造方法喷他多和连接进行订单公开(公告)号:EP2519100A4
公开(公告)日:2013-06-26
申请号:EP10840701
申请日:2010-12-26
申请人: MAPI PHARMA LTD
发明人: MAROM EHUD , MIZHIRITSKII MICHAEL
IPC分类号: C07C67/303 , C07C67/343 , C07C69/734 , C07C213/02 , C07C213/08 , C07C215/54 , C07C217/62 , C07C231/02 , C07C231/18 , C07C235/34 , C07F9/40
CPC分类号: C07C231/02 , C07B2200/07 , C07C67/303 , C07C67/343 , C07C213/02 , C07C213/08 , C07C231/18 , C07C235/34 , C07F9/4006 , C07C69/734 , C07C215/54 , C07C217/62
-
9.
公开(公告)号:EP2528923A4
公开(公告)日:2013-06-19
申请号:EP11736707
申请日:2011-01-24
申请人: MAPI PHARMA LTD
发明人: MIZHIRITSKII MICHAEL , MAROM EHUD
IPC分类号: C07D493/04 , C07C69/675
CPC分类号: C07D493/04
-
公开(公告)号:EP3259262A4
公开(公告)日:2018-08-01
申请号:EP15882498
申请日:2015-02-17
申请人: MAPI PHARMA LTD
发明人: MAROM EHUD , RUBNOV SHAI
IPC分类号: C07D213/64 , A61K31/444 , A61P25/08
CPC分类号: A61K31/444 , C07D213/64 , C07D401/04
摘要: The present invention describes a process for the synthesis of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-di-hydro-pyridin-2-one (Perampanel) represented by the structure of formula (1), and salts thereof, especially salts with pharmaceutically acceptable acids. The present invention further relates to certain intermediates formed and/or used in such process.
-
-
-
-
-
-
-
-
-